Free Trial

Thermo Fisher Scientific (TMO) Financials

Thermo Fisher Scientific logo
$452.77 -12.23 (-2.63%)
As of 12:43 PM Eastern
This is a fair market value price provided by Massive. Learn more.
Annual Income Statements for Thermo Fisher Scientific

Annual Income Statements for Thermo Fisher Scientific

This table shows Thermo Fisher Scientific's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders
1,975 2,022 2,225 2,938 3,696 6,375 7,725 6,950 5,995 6,335 6,704
Consolidated Net Income / (Loss)
1,975 2,022 2,225 2,938 3,698 6,377 7,728 6,960 5,955 6,338 6,721
Net Income / (Loss) Continuing Operations
1,980 2,025 2,228 2,938 3,698 6,377 7,728 6,960 5,955 6,338 6,720
Total Pre-Tax Income
1,936 2,024 2,429 3,262 4,072 7,230 8,841 7,835 6,298 7,037 7,308
Total Operating Income
2,336 2,458 2,960 3,783 4,594 7,794 10,028 8,393 6,859 7,337 7,746
Total Gross Profit
7,756 8,372 9,448 10,857 11,328 16,004 19,638 18,971 17,100 17,702 18,238
Total Revenue
16,965 18,274 20,918 24,358 25,542 32,218 39,211 44,915 42,857 42,879 44,556
Operating Revenue
16,965 18,274 20,918 24,358 25,542 32,218 39,211 44,915 42,857 42,879 44,556
Total Cost of Revenue
9,209 9,902 11,470 13,501 14,214 16,214 19,573 25,944 25,757 25,177 26,318
Operating Cost of Revenue
9,209 9,902 11,470 13,501 14,214 16,214 19,573 25,944 25,757 25,177 26,318
Total Operating Expenses
5,420 5,914 6,488 7,074 6,734 8,210 9,610 10,578 10,241 10,364 10,491
Selling, General & Admin Expense
4,612 4,971 5,504 6,057 6,144 6,930 8,007 8,993 8,445 8,595 8,732
Research & Development Expense
692 754 887 967 1,003 1,181 1,406 1,471 1,337 1,390 1,397
Restructuring Charge
116 189 97 50 -413 99 197 114 459 379 362
Total Other Income / (Expense), net
-400 -434 -531 -521 -522 -564 -1,187 -558 -561 -300 -438
Interest Expense
- - 592 667 676 553 536 726 1,375 1,390 1,419
Interest & Investment Income
- - 81 137 224 65 43 272 879 1,078 993
Other Income / (Expense), net
-400 -434 -20 9.00 -70 -76 -694 -104 -65 12 -12
Income Tax Expense
-44 -1.00 201 324 374 850 1,109 703 284 657 547
Other Gains / (Losses), net
- - - - 0.00 -3.00 -4.00 -172 -59 -42 -41
Net Income / (Loss) Attributable to Noncontrolling Interest
- - - - 2.00 2.00 3.00 10 -40 3.00 17
Basic Earnings per Share
$4.96 $5.12 $5.64 $7.31 $9.24 $16.09 $19.62 $17.75 $15.52 $16.58 $17.77
Weighted Average Basic Shares Outstanding
399M 395M 395M 402M 400M 396M 394M 392M 386M 382M 377M
Diluted Earnings per Share
$4.92 $5.09 $5.59 $7.24 $9.17 $15.96 $19.46 $17.63 $15.45 $16.53 $17.74
Weighted Average Diluted Shares Outstanding
402M 397M 398M 406M 403M 399M 397M 394M 388M 383M 378M
Weighted Average Basic & Diluted Shares Outstanding
398.30M 394.90M 394.50M 401.90M 398.83M 393.79M 391.19M 385.43M 381.31M 377.26M 371.48M
Cash Dividends to Common per Share
$0.60 $0.60 $0.60 $0.68 $0.76 $0.88 $1.04 $1.20 $1.40 $1.56 $1.72

Quarterly Income Statements for Thermo Fisher Scientific

This table shows Thermo Fisher Scientific's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/30/2024 6/29/2024 9/28/2024 12/31/2024 3/29/2025 6/28/2025 9/27/2025 12/31/2025 3/28/2026
Net Income / (Loss) Attributable to Common Shareholders
1,715 1,630 1,328 1,548 1,630 1,829 1,507 1,617 1,616 1,964 1,651
Consolidated Net Income / (Loss)
1,695 1,606 1,331 1,553 1,629 1,825 1,511 1,618 1,621 1,971 1,656
Net Income / (Loss) Continuing Operations
1,695 1,606 1,331 1,553 1,629 1,825 1,511 1,619 1,621 1,969 1,656
Total Pre-Tax Income
1,765 1,740 1,589 1,765 1,742 1,941 1,620 1,709 1,826 2,153 1,734
Total Operating Income
1,864 1,854 1,663 1,820 1,838 2,016 1,716 1,834 1,941 2,255 1,863
Total Gross Profit
4,316 4,393 4,205 4,347 4,328 4,822 4,235 4,409 4,583 5,011 4,430
Total Revenue
10,574 10,886 10,345 10,541 10,598 11,395 10,364 10,855 11,122 12,215 11,005
Operating Revenue
10,574 10,886 10,345 10,541 10,598 11,395 10,364 10,855 11,122 12,215 11,005
Total Cost of Revenue
6,258 6,493 6,140 6,194 6,270 6,573 6,129 6,446 6,539 7,204 6,575
Operating Cost of Revenue
6,258 6,493 6,140 6,194 6,270 6,573 6,129 6,446 6,539 7,204 6,575
Total Operating Expenses
2,452 2,539 2,543 2,527 2,489 2,805 2,518 2,574 2,643 2,756 2,566
Selling, General & Admin Expense
2,049 2,132 2,183 2,111 2,098 2,203 2,078 2,140 2,162 2,352 2,181
Research & Development Expense
319 327 331 339 346 374 342 352 346 357 336
Restructuring Charge
84 80 29 77 45 228 98 82 135 47 49
Total Other Income / (Expense), net
-99 -114 -74 -54 -95 -77 -97 -126 -115 -100 -130
Interest Expense
359 390 363 354 356 317 303 404 347 365 354
Interest & Investment Income
246 309 279 295 277 227 203 297 234 259 233
Other Income / (Expense), net
14 -33 10 5.00 -16 13 3.00 -19 -2.00 6.00 -9.00
Income Tax Expense
53 133 281 128 99 149 95 92 207 153 70
Other Gains / (Losses), net
-17 -1.00 23 -84 -14 33 -14 2.00 2.00 -31 -8.00
Net Income / (Loss) Attributable to Noncontrolling Interest
-20 -24 4.00 6.00 0.00 -7.00 4.00 2.00 5.00 6.00 5.00
Basic Earnings per Share
$4.44 $4.21 $3.47 $4.05 $4.26 $4.80 $3.99 $4.28 $4.28 $5.22 $4.44
Weighted Average Basic Shares Outstanding
386M 386M 382M 382M 382M 382M 378M 378M 378M 377M 372M
Diluted Earnings per Share
$4.42 $4.20 $3.46 $4.04 $4.25 $4.78 $3.98 $4.28 $4.27 $5.21 $4.43
Weighted Average Diluted Shares Outstanding
388M 388M 384M 383M 384M 383M 379M 378M 378M 378M 373M
Weighted Average Basic & Diluted Shares Outstanding
386.37M 381.31M 381.72M 382.00M 382.50M 377.26M 377.49M 377.61M 375.71M 371.48M 371.62M
Cash Dividends to Common per Share
$0.35 - $0.39 $0.39 - - $0.43 $0.43 - - $0.47

Annual Cash Flow Statements for Thermo Fisher Scientific

This table details how cash moves in and out of Thermo Fisher Scientific's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents
-898 345 130 1,053 305 7,914 -5,845 4,046 -440 -4,057 5,839
Net Cash From Operating Activities
2,942 3,258 4,005 4,543 4,973 8,289 9,312 9,154 8,406 8,667 7,818
Net Cash From Continuing Operating Activities
2,951 3,260 4,006 4,543 4,973 8,289 9,312 9,154 8,406 8,667 7,819
Net Income / (Loss) Continuing Operations
1,980 2,025 2,228 2,938 3,698 6,377 7,728 6,960 5,955 6,338 6,721
Consolidated Net Income / (Loss)
1,975 2,022 2,225 2,938 3,698 6,377 7,728 6,960 5,955 6,338 6,721
Depreciation Expense
1,688 1,758 439 526 564 658 831 986 1,068 1,156 1,050
Amortization Expense
- - 1,594 1,741 1,713 1,667 1,761 2,395 2,338 1,952 1,730
Non-Cash Adjustments To Reconcile Net Income
155 232 149 194 -85 438 1,374 462 1,092 602 348
Changes in Operating Assets and Liabilities, net
-872 -755 -404 -856 -917 -851 -2,382 -1,649 -2,047 -1,381 -2,030
Net Cash From Investing Activities
-1,093 -5,520 -7,729 -1,253 -1,487 -1,510 -21,932 -2,159 -5,142 -5,841 -4,047
Net Cash From Continuing Investing Activities
-1,093 -5,520 -7,729 -1,253 -1,487 -1,510 -21,932 -2,159 -5,142 -5,841 -4,047
Purchase of Property, Plant & Equipment
-423 -444 -508 -758 -926 -1,474 -2,523 -2,243 -1,479 -1,400 -1,525
Acquisitions
-695 -5,178 -7,226 -536 -1,843 -38 -19,395 -39 -3,660 -3,132 -4,037
Purchase of Investments
- - - - - - - -52 -208 -3,396 -383
Sale of Property, Plant & Equipment
18 26 7.00 50 36 8.00 20 24 87 57 44
Sale and/or Maturity of Investments
12 - - - - - - 116 15 1,770 1,565
Other Investing Activities, net
-5.00 76 -2.00 -9.00 118 -6.00 -34 35 103 260 289
Net Cash From Financing Activities
-2,617 2,759 3,854 -2,237 -3,118 959 6,581 -2,810 -3,622 -6,792 1,801
Net Cash From Continuing Financing Activities
-2,617 2,759 3,854 -2,237 -3,118 959 6,581 -2,810 -3,622 -6,791 1,801
Repayment of Debt
-11,680 -12,626 -11,816 -7,357 -9,893 -1,051 -11,673 -4,074 -7,661 -3,412 -3,417
Repurchase of Common Equity
-500 -1,250 -750 -500 -1,500 -1,500 -2,000 -3,000 -3,000 -4,000 -3,000
Payment of Dividends
-241 -238 -237 -266 -297 -337 -395 -455 -523 -583 -636
Issuance of Debt
9,732 16,786 14,839 5,750 8,419 3,847 20,649 4,719 7,562 1,204 8,854
Effect of Exchange Rate Changes
-130 -152 - - -63 176 194 -139 -82 -91 267

Quarterly Cash Flow Statements for Thermo Fisher Scientific

This table details how cash moves in and out of Thermo Fisher Scientific's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/30/2024 6/29/2024 9/28/2024 12/31/2024 3/29/2025 6/28/2025 9/27/2025 12/31/2025 3/28/2026
Net Change in Cash & Equivalents
3,015 1,929 -2,578 1,578 -2,427 -630 132 431 -2,592 7,868 -6,599
Net Cash From Operating Activities
2,414 3,723 1,251 1,960 2,166 3,290 723 1,399 2,239 3,457 1,192
Net Cash From Continuing Operating Activities
2,414 3,723 1,250 1,963 2,163 3,291 722 1,401 2,238 3,458 1,193
Net Income / (Loss) Continuing Operations
1,695 1,606 1,331 1,554 1,629 1,824 1,511 1,619 1,621 1,970 1,656
Consolidated Net Income / (Loss)
1,695 1,606 1,331 1,554 1,629 1,824 1,511 1,619 1,621 1,970 1,656
Depreciation Expense
269 276 285 277 290 304 276 256 226 292 306
Amortization Expense
584 563 551 514 449 438 429 430 435 436 430
Non-Cash Adjustments To Reconcile Net Income
178 434 123 188 165 126 210 144 187 -193 171
Changes in Operating Assets and Liabilities, net
-312 844 -1,040 -570 -370 599 -1,704 -1,048 -231 953 -1,370
Net Cash From Investing Activities
-1,181 -376 -2,030 -253 -3,578 20 -527 -288 -4,123 891 -8,961
Net Cash From Continuing Investing Activities
-1,181 -376 -2,030 -253 -3,577 19 -526 -288 -4,125 892 -8,962
Purchase of Property, Plant & Equipment
-332 -405 -347 -301 -272 -480 -362 -294 -404 -465 -376
Acquisitions
-909 - - - -3,132 - 0.00 - - - -8,872
Purchase of Investments
-12 -8.00 -1,758 -20 -287 -1,331 -264 -47 -40 -32 -14
Sale of Property, Plant & Equipment
66 11 4.00 16 20 17 12 1.00 4.00 27 9.00
Sale and/or Maturity of Investments
- - - - - - 2.00 - - 1,311 250
Other Investing Activities, net
6.00 11 71 52 94 43 86 52 98 51 41
Net Cash From Financing Activities
1,855 -1,428 -1,821 -115 -1,190 -3,666 -102 -991 -632 3,526 1,093
Net Cash From Continuing Financing Activities
1,855 -1,428 -1,820 -115 -1,190 -3,666 -102 -991 -632 3,526 1,092
Repayment of Debt
-1,476 -3,768 110 35 -1,040 -2,517 -793 -829 -601 -1,194 -1,373
Repurchase of Common Equity
- - -3,000 - - -1,000 -2,000 - -963 -37 -3,000
Payment of Dividends
-135 -136 -135 -149 -150 -149 -149 -162 -163 -162 -162
Issuance of Debt
3,466 2,476 1,205 -1.00 - - 2,840 - 1,095 4,919 5,627
Effect of Exchange Rate Changes
-73 10 22 -15 175 -273 37 311 -75 -6.00 78

Annual Balance Sheets for Thermo Fisher Scientific

This table presents Thermo Fisher Scientific's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets
40,834 45,908 56,669 56,232 58,381 69,052 95,123 97,154 98,726 97,321 110,343
Total Current Assets
5,741 7,021 9,421 10,625 11,893 21,957 20,113 25,229 24,589 22,137 28,707
Cash & Equivalents
452 786 1,335 2,103 2,399 10,325 4,477 8,524 8,077 4,009 9,852
Short-Term Investments
- - - - - - - - 3.00 1,561 253
Accounts Receivable
2,545 3,049 3,879 4,136 4,349 5,741 7,977 8,115 8,221 8,191 8,900
Inventories, net
1,992 2,213 2,971 3,005 3,370 4,029 5,051 5,634 5,088 4,978 5,425
Other Current Assets
534 595 1,236 1,381 1,775 1,862 2,608 2,956 3,200 3,399 4,278
Plant, Property, & Equipment, net
2,449 2,578 4,047 4,165 4,749 5,912 8,333 9,280 9,448 9,306 10,565
Total Noncurrent Assets
32,644 36,309 43,201 41,442 41,739 41,183 66,677 62,645 64,689 65,878 71,071
Goodwill
18,828 21,328 25,290 25,347 25,714 26,041 41,924 41,196 44,020 45,853 49,362
Intangible Assets
12,758 13,969 16,684 14,978 14,014 12,685 20,113 17,442 16,670 15,533 15,838
Other Noncurrent Operating Assets
1,058 1,012 1,227 1,117 2,011 2,457 4,640 4,007 3,999 4,492 5,871
Total Liabilities & Shareholders' Equity
40,834 45,908 56,669 56,232 58,381 69,052 95,123 97,154 98,726 97,321 110,343
Total Liabilities
19,484 24,368 31,256 28,646 28,706 34,535 54,146 53,006 51,884 47,650 56,807
Total Current Liabilities
4,146 4,866 7,048 6,147 6,197 10,304 13,436 17,010 14,012 13,332 15,189
Short-Term Debt
1,052 1,255 2,135 1,271 676 2,628 2,537 5,579 3,609 2,214 3,533
Accounts Payable
822 926 1,428 1,615 1,920 2,175 2,867 3,381 2,872 3,079 3,622
Current Deferred Revenue
318 486 719 - - - 2,655 2,601 2,689 2,852 2,710
Current Employee Benefit Liabilities
598 709 918 982 1,010 1,916 2,427 2,095 1,596 1,988 1,995
Other Current Liabilities
1,144 1,490 1,848 2,279 2,591 3,585 2,950 3,354 3,246 3,199 3,329
Total Noncurrent Liabilities
15,338 19,502 24,208 22,499 22,509 24,231 40,710 35,996 37,872 34,318 41,618
Long-Term Debt
11,420 15,372 18,873 17,719 17,076 19,107 32,333 28,909 31,308 29,061 35,852
Noncurrent Deferred & Payable Income Tax Liabilities
2,623 2,557 2,766 2,265 2,192 1,794 3,837 2,849 1,922 1,268 1,493
Other Noncurrent Operating Liabilities
1,295 1,573 2,569 2,515 3,241 3,330 4,540 4,238 4,642 3,989 4,273
Redeemable Noncontrolling Interest
- - - - - - 122 116 118 120 122
Total Equity & Noncontrolling Interests
21,350 21,540 25,413 27,586 29,675 34,517 40,855 44,032 46,724 49,551 53,415
Total Preferred & Common Equity
21,350 21,540 25,413 27,586 29,675 34,507 40,793 43,978 46,735 49,584 53,407
Preferred Stock
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity
21,350 21,540 25,413 27,586 29,675 34,507 40,793 43,978 46,735 49,585 53,407
Common Stock
12,213 12,555 14,605 15,053 15,498 16,016 16,613 17,184 17,728 18,406 19,008
Retained Earnings
12,142 13,927 15,914 18,696 22,092 28,116 35,431 41,910 47,364 53,102 59,156
Treasury Stock
-1,008 -2,306 -3,103 -3,665 -5,236 -6,818 -8,922 -12,017 -15,133 -19,226 -22,309
Accumulated Other Comprehensive Income / (Loss)
-1,997 -2,636 -2,003 -2,498 -2,679 -2,807 -2,329 -3,099 -3,224 -2,697 -2,448
Noncontrolling Interest
- - - - - 10 62 54 -11 -33 7.00

Quarterly Balance Sheets for Thermo Fisher Scientific

This table presents Thermo Fisher Scientific's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026
Period end date 7/1/2023 9/30/2023 12/31/2023 3/30/2024 6/29/2024 9/28/2024 12/31/2024 3/29/2025 6/28/2025 9/27/2025 3/28/2026
Total Assets
94,105 97,057 98,726 97,095 98,496 100,364 97,321 99,041 101,230 103,020 113,281
Total Current Assets
19,995 23,092 24,589 23,640 25,476 23,783 22,137 23,378 24,584 22,295 22,316
Cash & Equivalents
3,133 6,151 8,077 5,499 7,073 4,645 4,009 4,134 4,576 1,982 3,254
Short-Term Investments
- - 3.00 1,751 1,750 2,000 1,561 1,813 1,814 1,564 2.00
Accounts Receivable
8,019 8,370 8,221 7,931 7,943 8,255 8,191 8,455 8,594 8,911 9,204
Inventories, net
5,655 5,404 5,088 5,133 5,198 5,430 4,978 5,224 5,559 5,745 5,496
Other Current Assets
3,188 3,167 3,200 3,326 3,512 3,452 3,399 3,753 4,040 4,092 4,361
Plant, Property, & Equipment, net
9,292 9,167 9,448 9,324 9,282 9,412 9,306 9,331 9,635 10,177 10,658
Total Noncurrent Assets
64,818 64,798 64,689 64,132 63,739 67,168 65,878 66,332 67,012 70,548 80,306
Goodwill
43,273 43,583 44,020 43,843 43,843 46,726 45,853 46,493 47,249 49,287 55,187
Intangible Assets
17,437 17,091 16,670 16,048 15,519 16,262 15,533 15,323 15,148 16,242 19,146
Other Noncurrent Operating Assets
4,108 4,124 3,999 4,241 4,377 4,180 4,492 4,516 4,615 5,019 5,973
Total Liabilities & Shareholders' Equity
94,105 97,057 98,726 97,095 98,496 100,364 97,321 99,041 101,230 103,020 113,281
Total Liabilities
50,190 51,593 51,884 51,472 50,963 51,264 47,650 49,556 50,627 51,865 61,220
Total Current Liabilities
14,112 14,158 14,012 13,937 14,772 14,601 13,332 13,174 12,718 14,888 14,621
Short-Term Debt
4,814 4,795 3,609 4,451 5,121 4,116 2,214 2,819 2,214 3,823 3,090
Accounts Payable
2,423 2,508 2,872 2,555 2,547 2,606 3,079 3,049 2,980 3,120 3,344
Current Deferred Revenue
2,590 2,547 2,689 2,632 2,591 2,663 2,852 2,866 2,805 2,852 2,928
Current Employee Benefit Liabilities
1,310 1,460 1,596 1,314 1,495 1,823 1,988 1,419 1,518 1,884 1,565
Other Current Liabilities
2,975 2,848 3,246 2,985 3,019 3,393 3,199 3,022 3,200 3,209 3,694
Total Noncurrent Liabilities
36,078 37,435 37,872 37,535 36,191 36,663 34,318 36,382 37,909 36,977 46,599
Long-Term Debt
29,194 30,489 31,308 31,157 30,284 31,197 29,061 31,370 33,015 31,857 40,071
Noncurrent Deferred & Payable Income Tax Liabilities
2,842 2,620 1,922 1,811 1,516 1,123 1,268 1,041 624 842 2,107
Other Noncurrent Operating Liabilities
4,042 4,326 4,642 4,567 4,391 4,343 3,989 3,971 4,270 4,278 4,421
Redeemable Noncontrolling Interest
113 118 118 119 115 127 120 128 126 129 121
Total Equity & Noncontrolling Interests
43,802 45,346 46,724 45,504 47,419 48,972 49,551 49,357 50,476 51,024 51,940
Total Preferred & Common Equity
43,752 45,328 46,735 45,516 47,432 48,992 49,584 49,390 50,512 51,018 51,934
Preferred Stock
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity
43,752 45,328 46,735 45,517 47,432 48,992 49,585 49,390 50,511 51,018 51,933
Common Stock
17,471 17,607 17,728 17,925 18,092 18,275 18,406 18,555 18,676 18,775 19,158
Retained Earnings
44,289 45,869 47,364 48,542 49,940 51,421 53,102 54,447 55,901 57,354 60,632
Treasury Stock
-15,084 -15,121 -15,133 -18,186 -18,187 -18,227 -19,226 -21,269 -21,269 -22,310 -25,360
Accumulated Other Comprehensive Income / (Loss)
-2,924 -3,027 -3,224 -2,764 -2,413 -2,477 -2,697 -2,343 -2,797 -2,801 -2,497
Noncontrolling Interest
50 18 -11 -12 -12 -20 -33 -33 -35 7.00 7.00

Annual Metrics And Ratios for Thermo Fisher Scientific

This table displays calculated financial ratios and metrics derived from Thermo Fisher Scientific's official financial filings.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Growth Metrics
- - - - - - - - - - -
Revenue Growth
0.45% 7.72% 14.47% 16.45% 4.86% 26.14% 21.71% 14.55% -4.58% 0.05% 3.91%
EBITDA Growth
-3.92% 4.36% 31.49% 21.84% 12.25% 47.67% 18.75% -2.15% -12.60% 2.52% 0.55%
EBIT Growth
-7.24% 4.55% 45.26% 28.98% 19.30% 70.60% 20.94% -11.20% -18.04% 8.17% 5.24%
NOPAT Growth
5.10% 2.94% 10.40% 25.49% 22.45% 64.85% 27.52% -12.89% -14.27% 1.56% 7.73%
Net Income Growth
4.25% 2.38% 10.04% 32.04% 25.87% 72.44% 21.19% -9.94% -14.44% 6.43% 6.04%
EPS Growth
4.46% 3.46% 9.82% 29.52% 26.66% 74.05% 21.93% -9.40% -12.37% 6.99% 7.32%
Operating Cash Flow Growth
12.31% 10.74% 22.93% 13.43% 9.47% 66.68% 12.34% -1.70% -8.17% 3.10% -9.80%
Free Cash Flow Firm Growth
127.92% -155.66% -221.58% 180.57% -10.03% 65.29% -378.87% 153.37% -66.48% 66.09% -105.53%
Invested Capital Growth
-1.18% 12.02% 20.61% -1.36% 1.25% 2.00% 55.40% -1.76% 5.09% 2.30% 9.87%
Revenue Q/Q Growth
0.95% 1.67% 5.52% 1.92% 1.28% 13.06% 0.39% 1.69% -1.30% 1.20% 1.87%
EBITDA Q/Q Growth
1.14% 3.25% 18.58% 105.11% -5.38% 23.64% -7.29% 0.42% -0.82% 1.07% 2.12%
EBIT Q/Q Growth
2.39% 3.57% 30.03% 5.89% -8.22% 32.52% -9.84% -1.38% -1.09% 2.91% 3.09%
NOPAT Q/Q Growth
-0.06% 0.76% -4.71% 13.31% 4.15% 27.14% -4.37% -7.18% 0.54% 2.30% 3.37%
Net Income Q/Q Growth
0.05% 1.38% -4.37% 14.41% 2.95% 30.65% -9.81% -1.21% 0.54% 3.58% 2.22%
EPS Q/Q Growth
0.41% 1.60% -5.09% 14.56% 3.27% 30.71% -9.61% -0.96% 1.25% 3.64% 2.48%
Operating Cash Flow Q/Q Growth
15.71% -4.34% 19.76% -1.41% 2.30% 20.78% -8.65% 12.68% 2.89% -4.76% 2.18%
Free Cash Flow Firm Q/Q Growth
-12.23% 37.97% -10.81% -8.51% 5.24% 15.69% -370.76% 166.66% 58.16% 48.63% -119.41%
Invested Capital Q/Q Growth
-0.86% -3.16% -1.89% -0.21% -0.24% 1.21% 47.49% 0.21% -1.23% -3.07% -0.57%
Profitability Metrics
- - - - - - - - - - -
Gross Margin
45.72% 45.81% 45.17% 44.57% 44.35% 49.67% 50.08% 42.24% 39.90% 41.28% 40.93%
EBITDA Margin
21.36% 20.70% 23.77% 24.87% 26.63% 31.17% 30.41% 25.98% 23.80% 24.39% 23.60%
Operating Margin
13.77% 13.45% 14.15% 15.53% 17.99% 24.19% 25.57% 18.69% 16.00% 17.11% 17.38%
EBIT Margin
11.41% 11.08% 14.05% 15.57% 17.71% 23.96% 23.80% 18.45% 15.85% 17.14% 17.36%
Profit (Net Income) Margin
11.64% 11.06% 10.64% 12.06% 14.48% 19.79% 19.71% 15.50% 13.90% 14.78% 15.08%
Tax Burden Percent
102.01% 99.90% 91.60% 90.07% 90.82% 88.20% 87.41% 88.83% 94.55% 90.07% 91.97%
Interest Burden Percent
100.00% 100.00% 82.62% 86.02% 90.01% 93.68% 94.72% 94.52% 92.70% 95.75% 94.49%
Effective Tax Rate
-2.27% -0.05% 8.28% 9.93% 9.18% 11.76% 12.54% 8.97% 4.51% 9.34% 7.48%
Return on Invested Capital (ROIC)
7.12% 6.95% 6.58% 7.61% 9.32% 15.12% 14.95% 10.80% 9.11% 8.93% 9.06%
ROIC Less NNEP Spread (ROIC-NNEP)
3.84% 3.81% 3.82% 5.04% 6.38% 11.38% 9.97% 8.39% 6.86% 7.73% 7.44%
Return on Net Nonoperating Assets (RNNOA)
2.31% 2.48% 2.89% 3.48% 3.59% 4.75% 5.52% 5.55% 3.98% 4.21% 3.96%
Return on Equity (ROE)
9.43% 9.43% 9.48% 11.09% 12.92% 19.87% 20.47% 16.35% 13.09% 13.13% 13.02%
Cash Return on Invested Capital (CROIC)
8.30% -4.39% -12.10% 8.98% 8.08% 13.15% -28.43% 12.58% 4.15% 6.65% -0.35%
Operating Return on Assets (OROA)
4.63% 4.67% 5.73% 6.72% 7.89% 12.11% 11.37% 8.62% 6.94% 7.50% 7.45%
Return on Assets (ROA)
4.72% 4.66% 4.34% 5.20% 6.45% 10.01% 9.41% 7.24% 6.08% 6.47% 6.47%
Return on Common Equity (ROCE)
9.43% 9.43% 9.48% 11.09% 12.92% 19.87% 20.42% 16.28% 13.05% 13.11% 13.00%
Return on Equity Simple (ROE_SIMPLE)
9.25% 9.39% 8.76% 10.65% 12.46% 18.48% 18.94% 15.83% 12.74% 12.78% 0.00%
Net Operating Profit after Tax (NOPAT)
2,389 2,459 2,715 3,407 4,172 6,878 8,770 7,640 6,550 6,652 7,166
NOPAT Margin
14.08% 13.46% 12.98% 13.99% 16.33% 21.35% 22.37% 17.01% 15.28% 15.51% 16.08%
Net Nonoperating Expense Percent (NNEP)
3.28% 3.14% 2.76% 2.57% 2.94% 3.74% 4.99% 2.41% 2.25% 1.20% 1.62%
Return On Investment Capital (ROIC_SIMPLE)
- - - - - - - 9.73% 8.02% 8.23% 7.72%
Cost of Revenue to Revenue
54.28% 54.19% 54.83% 55.43% 55.65% 50.33% 49.92% 57.76% 60.10% 58.72% 59.07%
SG&A Expenses to Revenue
27.19% 27.20% 26.31% 24.87% 24.05% 21.51% 20.42% 20.02% 19.71% 20.04% 19.60%
R&D to Revenue
4.08% 4.13% 4.24% 3.97% 3.93% 3.67% 3.59% 3.28% 3.12% 3.24% 3.14%
Operating Expenses to Revenue
31.95% 32.36% 31.02% 29.04% 26.36% 25.48% 24.51% 23.55% 23.90% 24.17% 23.55%
Earnings before Interest and Taxes (EBIT)
1,936 2,024 2,940 3,792 4,524 7,718 9,334 8,289 6,794 7,349 7,734
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
3,624 3,782 4,973 6,059 6,801 10,043 11,926 11,670 10,200 10,457 10,514
Valuation Ratios
- - - - - - - - - - -
Price to Book Value (P/BV)
0.00 2.54 2.95 3.22 4.34 5.31 6.41 4.88 4.38 4.01 4.08
Price to Tangible Book Value (P/TBV)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Revenue (P/Rev)
0.00 2.99 3.58 3.65 5.05 5.68 6.66 4.78 4.77 4.64 4.89
Price to Earnings (P/E)
0.00 27.03 33.67 30.26 34.87 28.72 33.82 30.91 34.12 31.41 32.47
Dividend Yield
0.43% 0.43% 0.32% 0.31% 0.24% 0.19% 0.16% 0.22% 0.26% 0.30% 0.30%
Earnings Yield
0.00% 3.70% 2.97% 3.30% 2.87% 3.48% 2.96% 3.24% 2.93% 3.18% 3.08%
Enterprise Value to Invested Capital (EV/IC)
0.00 1.89 2.10 2.38 3.20 4.24 4.09 3.44 3.14 2.98 2.98
Enterprise Value to Revenue (EV/Rev)
0.00 3.86 4.52 4.34 5.65 6.04 7.44 5.36 5.40 5.24 5.55
Enterprise Value to EBITDA (EV/EBITDA)
0.00 18.64 19.02 17.46 21.21 19.37 24.47 20.65 22.69 21.50 23.50
Enterprise Value to EBIT (EV/EBIT)
0.00 34.83 32.17 27.90 31.88 25.20 31.27 29.07 34.07 30.59 31.95
Enterprise Value to NOPAT (EV/NOPAT)
0.00 28.67 34.84 31.05 34.57 28.28 33.28 31.54 35.34 33.79 34.48
Enterprise Value to Operating Cash Flow (EV/OCF)
0.00 21.64 23.62 23.29 29.01 23.47 31.34 26.32 27.54 25.94 31.61
Enterprise Value to Free Cash Flow (EV/FCFF)
0.00 0.00 0.00 26.32 39.88 32.53 0.00 27.08 77.60 45.37 0.00
Leverage & Solvency
- - - - - - - - - - -
Debt to Equity
0.58 0.77 0.83 0.69 0.60 0.63 0.85 0.78 0.75 0.63 0.74
Long-Term Debt to Equity
0.53 0.71 0.74 0.64 0.58 0.55 0.79 0.65 0.67 0.59 0.67
Financial Leverage
0.60 0.65 0.76 0.69 0.56 0.42 0.55 0.66 0.58 0.54 0.53
Leverage Ratio
2.00 2.02 2.18 2.13 2.00 1.99 2.17 2.26 2.15 2.03 2.01
Compound Leverage Factor
2.00 2.02 1.81 1.83 1.80 1.86 2.06 2.14 2.00 1.95 1.90
Debt to Total Capital
36.88% 43.56% 45.26% 40.77% 37.43% 38.64% 45.97% 43.86% 42.71% 38.64% 42.39%
Short-Term Debt to Total Capital
3.11% 3.29% 4.60% 2.73% 1.43% 4.67% 3.34% 7.09% 4.41% 2.74% 3.80%
Long-Term Debt to Total Capital
33.77% 40.28% 40.66% 38.04% 36.00% 33.97% 42.63% 36.76% 38.29% 35.90% 38.58%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.02% 0.24% 0.22% 0.13% 0.11% 0.14%
Common Equity to Total Capital
63.12% 56.44% 54.74% 59.23% 62.57% 61.34% 53.78% 55.93% 57.16% 61.26% 57.48%
Debt to EBITDA
3.44 4.40 4.22 3.13 2.61 2.16 2.92 2.96 3.42 2.99 3.75
Net Debt to EBITDA
3.32 4.19 3.96 2.79 2.26 1.14 2.55 2.22 2.63 2.46 2.78
Long-Term Debt to EBITDA
3.15 4.06 3.80 2.92 2.51 1.90 2.71 2.48 3.07 2.78 3.41
Debt to NOPAT
5.22 6.76 7.74 5.57 4.26 3.16 3.98 4.51 5.33 4.70 5.50
Net Debt to NOPAT
5.03 6.44 7.25 4.96 3.68 1.66 3.47 3.40 4.10 3.86 4.09
Long-Term Debt to NOPAT
4.78 6.25 6.95 5.20 4.09 2.78 3.69 3.78 4.78 4.37 5.00
Altman Z-Score
0.00 2.37 2.42 3.08 4.03 4.79 4.24 3.88 3.83 4.07 3.83
Noncontrolling Interest Sharing Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.02% 0.26% 0.42% 0.30% 0.20% 0.21%
Liquidity Ratios
- - - - - - - - - - -
Current Ratio
1.38 1.44 1.34 1.73 1.92 2.13 1.50 1.48 1.75 1.66 1.89
Quick Ratio
0.72 0.79 0.74 1.02 1.09 1.56 0.93 0.98 1.16 1.03 1.25
Cash Flow Metrics
- - - - - - - - - - -
Free Cash Flow to Firm (FCFF)
2,788 -1,552 -4,990 4,020 3,617 5,979 -16,673 8,898 2,983 4,954 -274
Operating Cash Flow to CapEx
726.42% 779.43% 799.40% 641.67% 558.76% 565.42% 372.03% 412.53% 603.88% 645.35% 527.89%
Free Cash Flow to Firm to Interest Expense
0.00 0.00 -8.43 6.03 5.35 10.81 -31.11 12.26 2.17 3.56 -0.19
Operating Cash Flow to Interest Expense
0.00 0.00 6.77 6.81 7.36 14.99 17.37 12.61 6.11 6.24 5.51
Operating Cash Flow Less CapEx to Interest Expense
0.00 0.00 5.92 5.75 6.04 12.34 12.70 9.55 5.10 5.27 4.47
Efficiency Ratios
- - - - - - - - - - -
Asset Turnover
0.41 0.42 0.41 0.43 0.45 0.51 0.48 0.47 0.44 0.44 0.43
Accounts Receivable Turnover
6.76 6.53 6.04 6.08 6.02 6.39 5.72 5.58 5.25 5.23 5.21
Inventory Turnover
4.78 4.71 4.43 4.52 4.46 4.38 4.31 4.86 4.80 5.00 5.06
Fixed Asset Turnover
6.96 7.27 6.31 5.93 5.73 6.04 5.51 5.10 4.58 4.57 4.48
Accounts Payable Turnover
11.21 11.33 9.75 8.87 8.04 7.92 7.76 8.30 8.24 8.46 7.85
Days Sales Outstanding (DSO)
53.99 55.87 60.44 60.05 60.63 57.16 63.85 65.39 69.56 69.85 70.00
Days Inventory Outstanding (DIO)
76.32 77.50 82.48 80.78 81.85 83.28 84.66 75.16 75.97 72.97 72.14
Days Payable Outstanding (DPO)
32.56 32.22 37.45 41.13 45.39 46.09 47.01 43.95 44.31 43.14 46.47
Cash Conversion Cycle (CCC)
97.75 101.14 105.47 99.70 97.09 94.34 101.50 96.60 101.23 99.68 95.68
Capital & Investment Metrics
- - - - - - - - - - -
Invested Capital
33,370 37,381 45,086 44,473 45,028 45,927 71,370 70,112 73,679 75,377 82,817
Invested Capital Turnover
0.51 0.52 0.51 0.54 0.57 0.71 0.67 0.63 0.60 0.58 0.56
Increase / (Decrease) in Invested Capital
-399 4,011 7,705 -613 555 899 25,443 -1,258 3,567 1,698 7,440
Enterprise Value (EV)
0.00 70,497 94,588 105,793 144,246 194,513 291,872 240,951 231,470 224,780 247,113
Market Capitalization
0.00 54,656 74,915 88,906 128,893 183,093 261,295 214,817 204,526 198,988 217,704
Book Value per Share
$53.51 $54.53 $63.37 $68.52 $74.00 $87.07 $103.52 $112.13 $120.96 $129.63 $142.15
Tangible Book Value per Share
($25.65) ($34.83) ($41.30) ($31.64) ($25.07) ($10.65) ($53.91) ($37.38) ($36.12) ($30.85) ($31.39)
Total Capital
33,822 38,167 46,421 46,576 47,427 56,252 75,847 78,636 81,759 80,946 92,922
Total Debt
12,472 16,627 21,008 18,990 17,752 21,735 34,870 34,488 34,917 31,275 39,385
Total Long-Term Debt
11,420 15,372 18,873 17,719 17,076 19,107 32,333 28,909 31,308 29,061 35,852
Net Debt
12,020 15,841 19,673 16,887 15,353 11,410 30,393 25,964 26,837 25,705 29,280
Capital Expenditures (CapEx)
405 418 501 708 890 1,466 2,503 2,219 1,392 1,343 1,481
Debt-free, Cash-free Net Working Capital (DFCFNWC)
2,195 2,624 3,173 3,646 3,973 3,956 4,737 5,274 6,106 5,449 6,946
Debt-free Net Working Capital (DFNWC)
2,647 3,410 4,508 5,749 6,372 14,281 9,214 13,798 14,186 11,019 17,051
Net Working Capital (NWC)
1,595 2,155 2,373 4,478 5,696 11,653 6,677 8,219 10,577 8,805 13,518
Net Nonoperating Expense (NNE)
414 437 490 469 474 501 1,042 680 595 314 445
Net Nonoperating Obligations (NNO)
12,020 15,841 19,673 16,887 15,353 11,410 30,393 25,964 26,837 25,706 29,280
Total Depreciation and Amortization (D&A)
1,688 1,758 2,033 2,267 2,277 2,325 2,592 3,381 3,406 3,108 2,780
Debt-free, Cash-free Net Working Capital to Revenue
12.94% 14.36% 15.17% 14.97% 15.55% 12.28% 12.08% 11.74% 14.25% 12.71% 15.59%
Debt-free Net Working Capital to Revenue
15.60% 18.66% 21.55% 23.60% 24.95% 44.33% 23.50% 30.72% 33.10% 25.70% 38.27%
Net Working Capital to Revenue
9.40% 11.79% 11.34% 18.38% 22.30% 36.17% 17.03% 18.30% 24.68% 20.53% 30.34%
Earnings Adjustments
- - - - - - - - - - -
Adjusted Basic Earnings per Share
$4.96 $5.12 $5.64 $7.31 $9.24 $16.09 $19.62 $17.75 $15.52 $16.58 $17.77
Adjusted Weighted Average Basic Shares Outstanding
398.70M 394.80M 395M 402M 400M 396M 394M 392M 386M 382M 377M
Adjusted Diluted Earnings per Share
$4.92 $5.09 $5.59 $7.24 $9.17 $15.96 $19.46 $17.63 $15.45 $16.53 $17.74
Adjusted Weighted Average Diluted Shares Outstanding
401.90M 397.40M 398M 406M 403M 399M 397M 394M 388M 383M 378M
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00 $0.00 $9.24 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
396.26M 390.39M 401.78M 399.00M 398.83M 393.79M 391.19M 385.43M 381.31M 377.26M 371.48M
Normalized Net Operating Profit after Tax (NOPAT)
1,716 1,853 2,804 3,452 3,797 6,965 8,942 7,744 6,988 6,996 7,501
Normalized NOPAT Margin
10.12% 10.14% 13.40% 14.17% 14.87% 21.62% 22.81% 17.24% 16.31% 16.31% 16.84%
Pre Tax Income Margin
11.41% 11.08% 11.61% 13.39% 15.94% 22.44% 22.55% 17.44% 14.70% 16.41% 16.40%
Debt Service Ratios
- - - - - - - - - - -
EBIT to Interest Expense
0.00 0.00 4.97 5.69 6.69 13.96 17.41 11.42 4.94 5.29 5.45
NOPAT to Interest Expense
0.00 0.00 4.59 5.11 6.17 12.44 16.36 10.52 4.76 4.79 5.05
EBIT Less CapEx to Interest Expense
0.00 0.00 4.12 4.62 5.38 11.31 12.74 8.36 3.93 4.32 4.41
NOPAT Less CapEx to Interest Expense
0.00 0.00 3.74 4.05 4.86 9.79 11.69 7.47 3.75 3.82 4.01
Payout Ratios
- - - - - - - - - - -
Dividend Payout Ratio
12.20% 11.77% 10.65% 9.05% 8.03% 5.28% 5.11% 6.54% 8.78% 9.20% 9.46%
Augmented Payout Ratio
37.52% 73.59% 44.36% 26.07% 48.59% 28.81% 30.99% 49.64% 59.16% 72.31% 54.10%

Quarterly Metrics And Ratios for Thermo Fisher Scientific

This table displays calculated financial ratios and metrics derived from Thermo Fisher Scientific's official financial filings.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/30/2024 6/29/2024 9/28/2024 12/31/2024 3/29/2025 6/28/2025 9/27/2025 12/31/2025 3/28/2026
DEI Shares Outstanding
- - - - - - - - - - 371,621,465.00
DEI Adjusted Shares Outstanding
- - - - - - - - - - 371,621,465.00
DEI Earnings Per Adjusted Shares Outstanding
- - - - - - - - - - 4.44
Growth Metrics
- - - - - - - - - - -
Revenue Growth
-0.96% -4.93% -3.41% -1.37% 0.23% 4.68% 0.18% 2.98% 4.94% 7.20% 6.18%
EBITDA Growth
7.35% -3.06% 5.60% 7.52% -6.22% 4.17% -3.39% -4.40% 1.52% 7.87% 6.85%
EBIT Growth
10.08% -3.96% 10.28% 15.65% -2.98% 11.42% 2.75% -0.55% 6.42% 11.43% 7.85%
NOPAT Growth
7.82% 1.93% -9.36% 11.01% -4.12% 8.70% 18.00% 2.80% -0.73% 12.55% 10.67%
Net Income Growth
13.15% 2.03% 3.02% 14.02% -3.89% 13.64% 13.52% 4.19% -0.49% 8.00% 9.60%
EPS Growth
16.62% 4.74% 4.22% 15.10% -3.85% 13.81% 15.03% 5.94% 0.47% 9.00% 11.31%
Operating Cash Flow Growth
24.63% 6.77% 71.60% 27.27% -10.27% -11.63% -42.21% -28.62% 3.37% 5.08% 64.87%
Free Cash Flow Firm Growth
85.83% -163.13% 249.93% 197.39% 49.11% 108.80% -233.53% -252.04% -164.80% -3,374.42% -484.67%
Invested Capital Growth
6.62% 5.09% -0.30% -0.90% 4.25% 2.30% 5.06% 7.19% 7.10% 9.87% 18.32%
Revenue Q/Q Growth
-1.06% 2.95% -4.97% 1.89% 0.54% 7.52% -9.05% 4.74% 2.46% 9.83% -9.91%
EBITDA Q/Q Growth
12.25% -2.60% -5.68% 4.26% -2.10% 8.20% -12.52% 3.18% 3.96% 14.96% -13.35%
EBIT Q/Q Growth
19.01% -3.04% -8.13% 9.09% -0.16% 11.36% -15.28% 5.58% 6.83% 16.61% -18.00%
NOPAT Q/Q Growth
18.90% -5.30% -20.05% 23.31% 2.70% 7.37% -13.21% 7.42% -0.82% 21.72% -14.65%
Net Income Q/Q Growth
24.45% -5.25% -17.12% 16.68% 4.89% 12.03% -17.21% 7.08% 0.19% 21.59% -15.98%
EPS Q/Q Growth
25.93% -4.98% -17.62% 16.76% 5.20% 12.47% -16.74% 7.54% -0.23% 22.01% -14.97%
Operating Cash Flow Q/Q Growth
56.75% 54.23% -66.40% 56.67% 10.51% 51.89% -78.02% 93.50% 60.04% 54.40% -65.52%
Free Cash Flow Firm Q/Q Growth
-16.26% 34.25% 185.99% 48.16% -160.75% 111.37% -1,404.58% -68.70% -5.80% -40.63% -132.94%
Invested Capital Q/Q Growth
-0.26% -1.23% 0.41% 0.18% 4.93% -3.07% 3.12% 2.21% 4.84% -0.57% 11.05%
Profitability Metrics
- - - - - - - - - - -
Gross Margin
40.82% 40.35% 40.65% 41.24% 40.84% 42.32% 40.86% 40.62% 41.21% 41.02% 40.25%
EBITDA Margin
25.83% 24.44% 24.25% 24.82% 24.16% 24.32% 23.39% 23.04% 23.38% 24.47% 23.53%
Operating Margin
17.63% 17.03% 16.08% 17.27% 17.34% 17.69% 16.56% 16.90% 17.45% 18.46% 16.93%
EBIT Margin
17.76% 16.73% 16.17% 17.31% 17.19% 17.81% 16.59% 16.72% 17.43% 18.51% 16.85%
Profit (Net Income) Margin
16.03% 14.75% 12.87% 14.73% 15.37% 16.02% 14.58% 14.91% 14.57% 16.14% 15.05%
Tax Burden Percent
96.03% 92.30% 83.76% 87.99% 93.51% 94.02% 93.27% 94.68% 88.77% 91.55% 95.50%
Interest Burden Percent
93.98% 95.55% 94.98% 96.71% 95.61% 95.66% 94.24% 94.16% 94.17% 95.22% 93.53%
Effective Tax Rate
3.00% 7.64% 17.68% 7.25% 5.68% 7.68% 5.86% 5.38% 11.34% 7.11% 4.04%
Return on Invested Capital (ROIC)
10.27% 9.38% 7.59% 9.11% 9.10% 9.40% 8.81% 9.00% 8.40% 9.66% 8.65%
ROIC Less NNEP Spread (ROIC-NNEP)
9.86% 8.97% 7.46% 8.64% 8.74% 9.26% 8.45% 8.57% 8.08% 9.21% 8.27%
Return on Net Nonoperating Assets (RNNOA)
6.12% 5.21% 5.10% 5.43% 5.34% 5.04% 5.03% 4.84% 4.90% 4.91% 5.55%
Return on Equity (ROE)
16.40% 14.58% 12.68% 14.54% 14.44% 14.44% 13.84% 13.84% 13.30% 14.57% 14.20%
Cash Return on Invested Capital (CROIC)
2.61% 4.15% 8.95% 9.74% 4.38% 6.65% 4.16% 2.11% 1.75% -0.35% -8.13%
Operating Return on Assets (OROA)
8.22% 7.32% 7.17% 7.61% 7.38% 7.79% 7.26% 7.24% 7.50% 7.94% 7.17%
Return on Assets (ROA)
7.42% 6.46% 5.70% 6.48% 6.60% 7.01% 6.38% 6.45% 6.27% 6.92% 6.41%
Return on Common Equity (ROCE)
16.34% 14.54% 12.64% 14.49% 14.40% 14.41% 13.81% 13.81% 13.27% 14.54% 14.17%
Return on Equity Simple (ROE_SIMPLE)
13.07% 0.00% 13.17% 13.04% 12.49% 0.00% 13.20% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)
1,808 1,712 1,369 1,688 1,734 1,861 1,615 1,735 1,721 2,095 1,788
NOPAT Margin
17.10% 15.73% 13.23% 16.01% 16.36% 16.33% 15.59% 15.99% 15.47% 17.15% 16.25%
Net Nonoperating Expense Percent (NNEP)
0.41% 0.40% 0.13% 0.47% 0.36% 0.14% 0.37% 0.42% 0.33% 0.45% 0.39%
Return On Investment Capital (ROIC_SIMPLE)
- 2.10% - - - 2.30% 1.93% 2.02% 1.98% 2.26% 1.88%
Cost of Revenue to Revenue
59.18% 59.65% 59.35% 58.76% 59.16% 57.68% 59.14% 59.38% 58.79% 58.98% 59.75%
SG&A Expenses to Revenue
19.38% 19.58% 21.10% 20.03% 19.80% 19.33% 20.05% 19.71% 19.44% 19.26% 19.82%
R&D to Revenue
3.02% 3.00% 3.20% 3.22% 3.26% 3.28% 3.30% 3.24% 3.11% 2.92% 3.05%
Operating Expenses to Revenue
23.19% 23.32% 24.58% 23.97% 23.49% 24.62% 24.30% 23.71% 23.76% 22.56% 23.32%
Earnings before Interest and Taxes (EBIT)
1,878 1,821 1,673 1,825 1,822 2,029 1,719 1,815 1,939 2,261 1,854
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
2,731 2,660 2,509 2,616 2,561 2,771 2,424 2,501 2,600 2,989 2,590
Valuation Ratios
- - - - - - - - - - -
Price to Book Value (P/BV)
4.30 4.38 4.93 4.45 4.79 4.01 3.82 3.05 3.44 4.08 3.39
Price to Tangible Book Value (P/TBV)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Revenue (P/Rev)
4.49 4.77 5.28 4.98 5.54 4.64 4.40 3.57 4.01 4.89 3.89
Price to Earnings (P/E)
32.80 34.12 37.19 33.93 38.25 31.41 28.97 23.41 26.69 32.47 25.68
Dividend Yield
0.27% 0.26% 0.25% 0.27% 0.25% 0.30% 0.32% 0.40% 0.36% 0.30% 0.37%
Earnings Yield
3.05% 2.93% 2.69% 2.95% 2.61% 3.18% 3.45% 4.27% 3.75% 3.08% 3.89%
Enterprise Value to Invested Capital (EV/IC)
3.00 3.14 3.42 3.21 3.39 2.98 2.79 2.30 2.49 2.98 2.35
Enterprise Value to Revenue (EV/Rev)
5.16 5.40 5.95 5.62 6.22 5.24 5.06 4.24 4.75 5.55 4.78
Enterprise Value to EBITDA (EV/EBITDA)
21.79 22.69 24.47 22.61 25.47 21.50 20.92 17.85 20.16 23.50 20.21
Enterprise Value to EBIT (EV/EBIT)
32.63 34.07 36.39 33.04 36.90 30.59 29.35 24.79 27.67 31.95 27.43
Enterprise Value to NOPAT (EV/NOPAT)
34.40 35.34 39.48 36.16 40.52 33.79 31.46 26.36 29.94 34.48 29.42
Enterprise Value to Operating Cash Flow (EV/OCF)
27.43 27.54 28.32 25.44 28.95 25.94 26.67 24.16 27.13 31.61 26.05
Enterprise Value to Free Cash Flow (EV/FCFF)
118.84 77.60 38.13 32.79 79.05 45.37 68.84 113.23 147.16 0.00 0.00
Leverage & Solvency
- - - - - - - - - - -
Debt to Equity
0.78 0.75 0.78 0.74 0.72 0.63 0.69 0.70 0.70 0.74 0.83
Long-Term Debt to Equity
0.67 0.67 0.68 0.64 0.64 0.59 0.63 0.65 0.62 0.67 0.77
Financial Leverage
0.62 0.58 0.68 0.63 0.61 0.54 0.60 0.56 0.61 0.53 0.67
Leverage Ratio
2.10 2.15 2.18 2.11 2.09 2.03 2.06 2.04 2.03 2.01 2.09
Compound Leverage Factor
1.98 2.06 2.07 2.04 2.00 1.94 1.94 1.92 1.91 1.92 1.96
Debt to Total Capital
43.70% 42.71% 43.84% 42.69% 41.83% 38.64% 40.86% 41.04% 41.09% 42.39% 45.33%
Short-Term Debt to Total Capital
5.94% 4.41% 5.48% 6.17% 4.88% 2.74% 3.37% 2.58% 4.40% 3.80% 3.25%
Long-Term Debt to Total Capital
37.76% 38.29% 38.36% 36.51% 36.96% 35.90% 37.49% 38.47% 36.69% 38.58% 42.08%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
0.17% 0.13% 0.13% 0.12% 0.13% 0.11% 0.11% 0.11% 0.16% 0.14% 0.13%
Common Equity to Total Capital
56.14% 57.16% 56.03% 57.19% 58.04% 61.26% 59.03% 58.85% 58.75% 57.48% 54.54%
Debt to EBITDA
3.43 3.42 3.45 3.37 3.41 2.99 3.30 3.43 3.47 3.75 4.04
Net Debt to EBITDA
2.83 2.63 2.74 2.53 2.77 2.46 2.72 2.81 3.12 2.78 3.74
Long-Term Debt to EBITDA
2.96 3.07 3.02 2.88 3.02 2.78 3.02 3.22 3.09 3.41 3.75
Debt to NOPAT
5.42 5.33 5.56 5.38 5.43 4.70 4.96 5.07 5.15 5.50 5.88
Net Debt to NOPAT
4.47 4.10 4.43 4.04 4.41 3.86 4.09 4.15 4.64 4.09 5.44
Long-Term Debt to NOPAT
4.68 4.78 4.86 4.61 4.80 4.37 4.55 4.75 4.60 5.00 5.46
Altman Z-Score
3.55 3.66 3.93 3.82 4.06 3.89 3.67 3.23 3.38 3.67 3.01
Noncontrolling Interest Sharing Ratio
0.35% 0.30% 0.32% 0.29% 0.26% 0.20% 0.21% 0.20% 0.24% 0.21% 0.22%
Liquidity Ratios
- - - - - - - - - - -
Current Ratio
1.63 1.75 1.70 1.72 1.63 1.66 1.77 1.93 1.50 1.89 1.53
Quick Ratio
1.03 1.16 1.09 1.14 1.02 1.03 1.09 1.18 0.84 1.25 0.85
Cash Flow Metrics
- - - - - - - - - - -
Free Cash Flow to Firm (FCFF)
-2,821 -1,855 1,595 2,363 -1,435 163 -2,130 -3,593 -3,801 -5,345 -12,451
Operating Cash Flow to CapEx
907.52% 944.92% 364.72% 687.72% 859.52% 710.58% 206.57% 477.47% 559.75% 789.27% 324.80%
Free Cash Flow to Firm to Interest Expense
-7.86 -4.76 4.39 6.68 -4.03 0.52 -7.03 -8.89 -10.95 -14.64 -35.17
Operating Cash Flow to Interest Expense
6.72 9.55 3.45 5.54 6.08 10.38 2.39 3.46 6.45 9.47 3.37
Operating Cash Flow Less CapEx to Interest Expense
5.98 8.54 2.50 4.73 5.38 8.92 1.23 2.74 5.30 8.27 2.33
Efficiency Ratios
- - - - - - - - - - -
Asset Turnover
0.46 0.44 0.44 0.44 0.43 0.44 0.44 0.43 0.43 0.43 0.43
Accounts Receivable Turnover
5.41 5.25 5.36 5.31 5.10 5.23 5.24 5.23 5.10 5.21 5.12
Inventory Turnover
4.69 4.80 4.69 4.62 4.63 5.00 4.86 4.73 4.60 5.06 4.99
Fixed Asset Turnover
4.88 4.58 4.55 4.56 4.56 4.57 4.60 4.57 4.47 4.48 4.52
Accounts Payable Turnover
10.49 8.24 9.46 10.09 9.82 8.46 8.98 9.20 8.97 7.85 8.37
Days Sales Outstanding (DSO)
67.42 69.56 68.09 68.79 71.61 69.85 69.71 69.84 71.63 70.00 71.30
Days Inventory Outstanding (DIO)
77.77 75.97 77.80 78.96 78.78 72.97 75.11 77.23 79.40 72.14 73.10
Days Payable Outstanding (DPO)
34.80 44.31 38.57 36.16 37.19 43.14 40.64 39.68 40.68 46.47 43.59
Cash Conversion Cycle (CCC)
110.39 101.23 107.32 111.59 113.20 99.68 104.18 107.39 110.34 95.68 100.81
Capital & Investment Metrics
- - - - - - - - - - -
Invested Capital
74,597 73,679 73,982 74,115 77,766 75,377 77,727 79,443 83,288 82,817 91,966
Invested Capital Turnover
0.60 0.60 0.57 0.57 0.56 0.58 0.57 0.56 0.54 0.56 0.53
Increase / (Decrease) in Invested Capital
4,629 3,567 -226 -675 3,169 1,698 3,745 5,328 5,522 7,440 14,239
Enterprise Value (EV)
224,108 231,470 252,876 237,774 263,481 224,780 217,028 183,053 207,573 247,113 215,879
Market Capitalization
194,839 204,526 224,411 211,089 234,706 198,988 188,691 154,123 175,303 217,704 175,846
Book Value per Share
$117.45 $120.96 $119.15 $124.26 $128.25 $129.63 $130.92 $133.81 $135.11 $142.15 $139.80
Tangible Book Value per Share
($39.76) ($36.12) ($37.63) ($31.25) ($36.64) ($30.85) ($32.94) ($31.49) ($38.43) ($31.39) ($60.30)
Total Capital
80,748 81,759 81,231 82,939 84,412 80,946 83,674 85,831 86,833 92,922 95,222
Total Debt
35,284 34,917 35,608 35,405 35,313 31,275 34,189 35,229 35,680 39,385 43,161
Total Long-Term Debt
30,489 31,308 31,157 30,284 31,197 29,061 31,370 33,015 31,857 35,852 40,071
Net Debt
29,133 26,837 28,358 26,582 28,668 25,705 28,242 28,839 32,134 29,280 39,905
Capital Expenditures (CapEx)
266 394 343 285 252 463 350 293 400 438 367
Debt-free, Cash-free Net Working Capital (DFCFNWC)
7,578 6,106 6,904 7,002 6,653 5,449 7,076 7,690 7,684 6,946 7,529
Debt-free Net Working Capital (DFNWC)
13,729 14,186 14,154 15,825 13,298 11,019 13,023 14,080 11,230 17,051 10,785
Net Working Capital (NWC)
8,934 10,577 9,703 10,704 9,182 8,805 10,204 11,866 7,407 13,518 7,695
Net Nonoperating Expense (NNE)
113 106 38 135 105 36 104 117 100 124 132
Net Nonoperating Obligations (NNO)
29,133 26,837 28,359 26,581 28,667 25,706 28,242 28,841 32,135 29,280 39,905
Total Depreciation and Amortization (D&A)
853 839 836 791 739 742 705 686 661 728 736
Debt-free, Cash-free Net Working Capital to Revenue
17.45% 14.25% 16.25% 16.54% 15.70% 12.71% 16.49% 17.80% 17.57% 15.59% 16.66%
Debt-free Net Working Capital to Revenue
31.62% 33.10% 33.31% 37.37% 31.39% 25.70% 30.36% 32.58% 25.68% 38.27% 23.86%
Net Working Capital to Revenue
20.58% 24.68% 22.83% 25.28% 21.67% 20.53% 23.79% 27.46% 16.94% 30.34% 17.03%
Earnings Adjustments
- - - - - - - - - - -
Adjusted Basic Earnings per Share
$4.44 $4.21 $3.47 $4.05 $4.26 $4.80 $3.99 $4.28 $4.28 $5.22 $4.44
Adjusted Weighted Average Basic Shares Outstanding
386M 386M 382M 382M 382M 382M 378M 378M 378M 377M 372M
Adjusted Diluted Earnings per Share
$4.42 $4.20 $3.46 $4.04 $4.25 $4.78 $3.98 $4.28 $4.27 $5.21 $4.43
Adjusted Weighted Average Diluted Shares Outstanding
388M 388M 384M 383M 384M 383M 379M 378M 378M 378M 373M
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
386.37M 381.31M 381.72M 382.00M 382.50M 377.26M 377.49M 377.61M 375.71M 371.48M 371.62M
Normalized Net Operating Profit after Tax (NOPAT)
1,890 1,786 1,393 1,759 1,776 2,072 1,708 1,813 1,841 2,138 1,835
Normalized NOPAT Margin
17.87% 16.41% 13.46% 16.69% 16.76% 18.18% 16.48% 16.70% 16.55% 17.51% 16.67%
Pre Tax Income Margin
16.69% 15.98% 15.36% 16.74% 16.44% 17.03% 15.63% 15.74% 16.42% 17.63% 15.76%
Debt Service Ratios
- - - - - - - - - - -
EBIT to Interest Expense
5.23 4.67 4.61 5.16 5.12 6.40 5.67 4.49 5.59 6.19 5.24
NOPAT to Interest Expense
5.04 4.39 3.77 4.77 4.87 5.87 5.33 4.30 4.96 5.74 5.05
EBIT Less CapEx to Interest Expense
4.49 3.66 3.66 4.35 4.41 4.94 4.52 3.77 4.44 4.99 4.20
NOPAT Less CapEx to Interest Expense
4.30 3.38 2.83 3.96 4.16 4.41 4.18 3.57 3.81 4.54 4.01
Payout Ratios
- - - - - - - - - - -
Dividend Payout Ratio
8.51% 8.78% 9.03% 8.97% 9.32% 9.20% 9.16% 9.27% 9.48% 9.46% 9.45%
Augmented Payout Ratio
76.04% 59.16% 59.08% 57.48% 58.34% 72.31% 55.19% 54.84% 69.75% 54.10% 67.71%

Financials Breakdown Chart

Key Financial Trends

Thermo Fisher Scientific (TMO) continues to demonstrate solid quarterly profitability and cash generation in its Q4 2025 results, alongside a strong, ongoing investment pace. Below are the key takeaways drawn from the last four years of quarterly statements, with a focus on the latest Q4 2025 data.

  • Q4 2025 revenue rose to $12.215B, continuing the upward trajectory seen through 2025 and marking a year-over-year lift vs. Q4 2024.
  • Total gross profit in Q4 2025 was $5.011B, yielding a gross margin around 41%—a stable, healthy margin given rising volume.
  • Net income in Q4 2025 climbed to about $1.971B (consolidated) and $1.969B (continuing operations), up from Q3 2025 levels and earlier quarters, signaling improving bottom-line leverage as revenue grows.
  • Net cash from continuing operating activities was $3.458B in Q4 2025, up from $2.238B in Q3 2025, indicating stronger operating cash flow generation.
  • Diluted earnings per share reached $5.21 in Q4 2025 (basic $5.22), reflecting a solid per-share earnings improvement versus the prior quarter (Q3 2025 diluted EPS around $4.27–$4.28).
  • Slightly lower weighted average shares outstanding (about 377.0M basic vs. 378.0M in Q3 2025) support per-share metrics without a major dilution event.
  • Net cash from financing activities turned positive in Q4 2025 at about $3.526B, aided by debt issuance of roughly $4.919B and favorable net borrowings.
  • Net change in cash and equivalents in Q4 2025 was approximately $7.868B, signaling a meaningful liquidity uptick for the period.
  • Capex remained manageable and cash-flow-accretive: purchases of property, plant & equipment were about $465M in Q4 2025, while operating cash flow exceeded this level, supporting near-term free cash flow generation.
  • Total gross profit for Q4 2025 increased to $5.011B, reinforcing the breadth of profitability alongside rising revenue.
05/11/26 10:59 AM ETAI Generated. May Contain Errors.

Thermo Fisher Scientific Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Thermo Fisher Scientific's financial year ends in December. Their financial year 2025 ended on December 31, 2025.

Thermo Fisher Scientific's net income appears to be on an upward trend, with a most recent value of $6.72 billion in 2025, rising from $1.98 billion in 2015. The previous period was $6.34 billion in 2024. View Thermo Fisher Scientific's forecast to see where analysts expect Thermo Fisher Scientific to go next.

Thermo Fisher Scientific's total operating income in 2025 was $7.75 billion, based on the following breakdown:
  • Total Gross Profit: $18.24 billion
  • Total Operating Expenses: $10.49 billion

Over the last 10 years, Thermo Fisher Scientific's total revenue changed from $16.97 billion in 2015 to $44.56 billion in 2025, a change of 162.6%.

Thermo Fisher Scientific's total liabilities were at $56.81 billion at the end of 2025, a 19.2% increase from 2024, and a 191.6% increase since 2015.

In the past 10 years, Thermo Fisher Scientific's cash and equivalents has ranged from $452.10 million in 2015 to $10.33 billion in 2020, and is currently $9.85 billion as of their latest financial filing in 2025.

Over the last 10 years, Thermo Fisher Scientific's book value per share changed from 53.51 in 2015 to 142.15 in 2025, a change of 165.7%.



Financial statements for NYSE:TMO last updated on 5/3/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners